Market Cap 116.23M
Revenue (ttm) 53.40M
Net Income (ttm) 2.93M
EPS (ttm) N/A
PE Ratio 37.50
Forward PE 8.33
Profit Margin 5.49%
Debt to Equity Ratio 0.00
Volume 414,000
Avg Vol 895,298
Day's Range N/A - N/A
Shares Out 79.61M
Stochastic %K 22%
Beta -0.23
Analysts Strong Sell
Price Target $14.00

Company Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 696 9345
Address:
2 University Plaza, Suite 100, Hackensack, United States
biostockhunter
biostockhunter Jul. 31 at 9:11 AM
$PLX seems US Fabrazyme growth stalling/downtrend, no? Now negative -0.7%
3 · Reply
brunoq14
brunoq14 Jul. 31 at 9:01 AM
$PLX If it is "obvious" that Chiesi will eventually buy Protalix, because that will be less expensive than fulfilling the contractual obligations already entered into, why does that not stabilize Protalix's share price?
1 · Reply
ElZocko2
ElZocko2 Jul. 31 at 8:55 AM
$PLX Imagine that our expectations, dreams, and calculations simply never become reality, because shortly before they do, new shares are issued again and assets are purchased with them. A rather frightening thought - and not that unrealistic.
1 · Reply
ToRni27
ToRni27 Jul. 31 at 8:50 AM
$PLX if we penetrate 20% of Sanofi‘s market than we are looking at 160M for Chiesi in US and EU. That means PLX gets as much as 24M in revenues per year from Elfabrio drug. Thats how reality looks like now. We need 55M in revenues per year to get above breakeven. GL. To be honest its not looking good if you add dilution. Only hope is 4 week dosing. The only way to get superior to standard of care since FDA stated that Elfabrio is not superior on approval date.
1 · Reply
Supreme10
Supreme10 Jul. 31 at 8:10 AM
$PLX Sanofi Q2 available
2 · Reply
pmcd777
pmcd777 Jul. 30 at 11:47 PM
$PLX well that didn't take long. Prasad departs to spend more time with the family. Announced today. https://www.pharmalive.com/us-fdas-top-vaccine-official-vinay-prasad-leaves-agency-after-short-stint/
0 · Reply
BryGuy29
BryGuy29 Jul. 30 at 9:32 PM
$PLX can’t wait for tomorrow! Tomorrow is the day!!! LFG !! Fingers crossed !🤞
1 · Reply
CliffordCapital
CliffordCapital Jul. 30 at 7:41 PM
$PLX Daby speaking facts !!
2 · Reply
Uktrader001
Uktrader001 Jul. 30 at 7:18 PM
0 · Reply
brunoq14
brunoq14 Jul. 30 at 4:29 PM
$PLX The May presentation introduced the Elelyso theme and put heavy emphasis on the promise of the gout drug. I'm sure we'll hear about the gout drug, but I'm not that certain about Elelyso. Too easy for them to put it off.
1 · Reply
Latest News on PLX
Protalix BioTherapeutics Issues 2025 Letter to Stockholders

Dec 23, 2024, 6:50 AM EST - 7 months ago

Protalix BioTherapeutics Issues 2025 Letter to Stockholders


Protalix BioTherapeutics Issues 2024 Letter to Stockholders

Dec 26, 2023, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics Issues 2024 Letter to Stockholders


biostockhunter
biostockhunter Jul. 31 at 9:11 AM
$PLX seems US Fabrazyme growth stalling/downtrend, no? Now negative -0.7%
3 · Reply
brunoq14
brunoq14 Jul. 31 at 9:01 AM
$PLX If it is "obvious" that Chiesi will eventually buy Protalix, because that will be less expensive than fulfilling the contractual obligations already entered into, why does that not stabilize Protalix's share price?
1 · Reply
ElZocko2
ElZocko2 Jul. 31 at 8:55 AM
$PLX Imagine that our expectations, dreams, and calculations simply never become reality, because shortly before they do, new shares are issued again and assets are purchased with them. A rather frightening thought - and not that unrealistic.
1 · Reply
ToRni27
ToRni27 Jul. 31 at 8:50 AM
$PLX if we penetrate 20% of Sanofi‘s market than we are looking at 160M for Chiesi in US and EU. That means PLX gets as much as 24M in revenues per year from Elfabrio drug. Thats how reality looks like now. We need 55M in revenues per year to get above breakeven. GL. To be honest its not looking good if you add dilution. Only hope is 4 week dosing. The only way to get superior to standard of care since FDA stated that Elfabrio is not superior on approval date.
1 · Reply
Supreme10
Supreme10 Jul. 31 at 8:10 AM
$PLX Sanofi Q2 available
2 · Reply
pmcd777
pmcd777 Jul. 30 at 11:47 PM
$PLX well that didn't take long. Prasad departs to spend more time with the family. Announced today. https://www.pharmalive.com/us-fdas-top-vaccine-official-vinay-prasad-leaves-agency-after-short-stint/
0 · Reply
BryGuy29
BryGuy29 Jul. 30 at 9:32 PM
$PLX can’t wait for tomorrow! Tomorrow is the day!!! LFG !! Fingers crossed !🤞
1 · Reply
CliffordCapital
CliffordCapital Jul. 30 at 7:41 PM
$PLX Daby speaking facts !!
2 · Reply
Uktrader001
Uktrader001 Jul. 30 at 7:18 PM
0 · Reply
brunoq14
brunoq14 Jul. 30 at 4:29 PM
$PLX The May presentation introduced the Elelyso theme and put heavy emphasis on the promise of the gout drug. I'm sure we'll hear about the gout drug, but I'm not that certain about Elelyso. Too easy for them to put it off.
1 · Reply
dannymac65
dannymac65 Jul. 30 at 3:59 PM
$PLX I find it interesting that Eyal is leaving in November BEFORE Chiesi confidentiality agreement expires. Is his replacement here simply to negotiate better terms?
5 · Reply
OldManLogan
OldManLogan Jul. 30 at 1:28 PM
$PLX Protalix should swing for the fences and announce they are developing a plant-based long acting bio better of the #GLP1 semaglutide... you could take it once a month and you'd never develop antibodies to it. $NVO OR $LLY might just buy us for a couple billion just to shelve that product, lol!
1 · Reply
Artfldgr
Artfldgr Jul. 30 at 11:55 AM
$PLX Clearly the world is just missing out on the once-in-a-lifetime investment of the century here. Let’s recap the comedy: The stock is priced at $1.46, which is basically couch-cushion money in the stock market world. Analysts are boldly predicting it will soar to $6.66 — and yes, that’s the actual number, not a demonic coincidence — representing a 356.16% increase. Because who wouldn't believe in quadrupling their investment overnight on a company you’ve never heard of outside of a biotech Reddit thread? 60% of analysts call it a “Strong Buy,” which in analyst-speak means: "Hey, if this doesn’t work out, we never said 'guaranteed' now, did we?" 0% say “Sell” — probably because the only people holding this stock are either die-hard believers or forgot they bought it back in 2019. And yet... crickets. No stampede. No meme stock frenzy. No Reddit rebellion. Not even a 5-cent bump. https://public.com/stocks/plx/forecast-price-target?wpsrc=Organic+Search&wpsn=www.google.com
0 · Reply
Artfldgr
Artfldgr Jul. 30 at 11:42 AM
$PLX Half a million shares traded and no movement... but if I say someone may be doing an ATM people get upset at ME, not the ATM. so. everything is nice... it's wonderful... don't worry about it if you have 100k shares... its only $1000 per penny. Be really nice if I am wrong, and the 10Q says they didn't do this, and so the missing 8K isn't an issue. But hey, what do I know? Maybe gravity just increased for a day and stocks trade lower for fun. I'm sure the missing 8-K is just out grabbing coffee, and that $1000 per penny drop? Pocket change—who doesn't enjoy a little spontaneous wealth evaporation? Everything is totally fine. Unicorns are real. Trust the process. 🌈✨
0 · Reply
jcon777
jcon777 Jul. 29 at 10:18 PM
$PLX I am curious of opinions here. If earnings is positive e.g. .03 in about two weeks, and then much more positive e.g. .07 for Q3, would/should we expect the forward PE of 8 to help catapult the stock price since we should have a reasonable baseline of good earnings for two quarters?
2 · Reply
BryGuy29
BryGuy29 Jul. 29 at 7:45 PM
$PLX where is this guy?
1 · Reply
Uktrader001
Uktrader001 Jul. 29 at 7:21 PM
$PLX let’s be objective, looking at the chart it’s not screaming buy.
3 · Reply
Uktrader001
Uktrader001 Jul. 29 at 7:12 PM
0 · Reply
Uktrader001
Uktrader001 Jul. 29 at 7:09 PM
$PLX Why so glum, just sit back and wait. February 2026 until then 1.5 great. Go find something else to trade. That’s what I’m doing. If PlX hits great. I won’t get fomo if it popped. I have more than enough.
0 · Reply
jcon777
jcon777 Jul. 29 at 6:21 PM
$PLX I asked Grok this question: "what are the chances that Elfabrio will get one month dosing?" The answer was very long. Here is part of the summary: "In the EU: The chances of approval for the 2 mg/kg every four weeks regimen appear moderate to high in the EU, given the EMA’s acceptance of the variation application and the supportive BRIGHT study data. Approval could occur within 1–2 years (by 2026–2027), assuming no major issues arise during the review and extension study data reinforce the findings. The EMA’s prior authorization of Elfabrio and acknowledgment of its efficacy in reducing Gb3 levels suggest a favorable regulatory environment."
0 · Reply
Artfldgr
Artfldgr Jul. 29 at 3:12 PM
0 · Reply
Artfldgr
Artfldgr Jul. 29 at 3:04 PM
0 · Reply